{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:51:12Z","timestamp":1790837472464,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.jacl.2017.06.015","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T08:07:51Z","timestamp":1498810071000},"page":"1223-1233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":138,"title":["Residual atherosclerotic cardiovascular disease risk in statin-treated adults: The Multi-Ethnic Study of Atherosclerosis"],"prefix":"10.1016","volume":"11","author":[{"given":"Nathan D.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanglu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben G.W.","family":"Quek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"Blumenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Budoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Cushman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parveen","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veit","family":"Sandfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Antonio G.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2017.06.015_bib1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2017.06.015_bib2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1475-2840-13-26","article-title":"Residual macrovascular risk in 2013: what have we learned?","volume":"13","author":"Fruchart","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"10.1016\/j.jacl.2017.06.015_bib3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jacl.2017.06.015_bib4","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.amjcard.2013.12.042","article-title":"Preventable Coronary Heart Disease Events from Control of Cardiovascular Risk Factors in US Adults with Diabetes (Projections from Utilizing the UKPDS Risk Engine)","volume":"113","author":"Wong","year":"2014","journal-title":"Am J Cardiol"},{"issue":"8934","key":"10.1016\/j.jacl.2017.06.015_bib5","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jacl.2017.06.015_bib6","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jacl.2017.06.015_bib7","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"issue":"9326","key":"10.1016\/j.jacl.2017.06.015_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.jacl.2017.06.015_bib9","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.jacl.2017.06.015_bib10","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"issue":"25","key":"10.1016\/j.jacl.2017.06.015_bib11","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jacl.2017.06.015_bib12","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jacc.2005.07.006","article-title":"The forgotten majority: unfinished business in cardiovascular risk reduction","volume":"46","author":"Libby","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"6 Suppl","key":"10.1016\/j.jacl.2017.06.015_bib13","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2015.09.002","article-title":"National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2","volume":"9","author":"Jacobson","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.jacl.2017.06.015_bib14","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","volume":"68","author":"Lloyd-Jones","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2017.06.015_bib15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","article-title":"National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1\u2014Full Report","volume":"9","author":"Jacobson","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2017.06.015_bib16","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/aje\/kwf113","article-title":"Multi-ethnic study of atherosclerosis: objectives and design","volume":"156","author":"Bild","year":"2002","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jacl.2017.06.015_bib17","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cll.2006.07.006","article-title":"Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy","volume":"26","author":"Jeyarajah","year":"2006","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.jacl.2017.06.015_bib18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.atherosclerosis.2008.08.045","article-title":"A twin study of heritability of plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) mass and activity","volume":"205","author":"Lenzini","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2017.06.015_bib19","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.2337\/dc09-0102","article-title":"Inflammatory, Hemostatic, and Other Novel Biomarkers for Diabetic Retinopathy","volume":"32","author":"Nguyen","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2017.06.015_bib20","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0735-1097(90)90282-T","article-title":"Quantification of coronary artery calcium using ultrafast computed tomography","volume":"15","author":"Agatston","year":"1990","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2017.06.015_bib21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1161\/CIRCULATIONAHA.105.580696","article-title":"Distribution of coronary artery calcium by race, gender, and age: results from the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"113","author":"McClelland","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2017.06.015_bib22","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2012.9624","article-title":"Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals","volume":"308","author":"Yeboah","year":"2012","journal-title":"JAMA"},{"issue":"25 Pt B","key":"10.1016\/j.jacl.2017.06.015_bib23","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2017.06.015_bib24","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2017.06.015_bib25","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2017.06.015_bib26","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1161\/CIRCULATIONAHA.111.088591","article-title":"Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study","volume":"125","author":"Mora","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2017.06.015_bib27","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2017.06.015_bib28","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1161\/STROKEAHA.113.004229","article-title":"Atherogenic dyslipidemia and cardiovascular residual risk in statin-treated patients","volume":"45","author":"Sirimarco","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.jacl.2017.06.015_bib29","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jacl.2015.05.003","article-title":"Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010","volume":"9","author":"Wong","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2017.06.015_bib30","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2337\/dc15-2439","article-title":"Cardiovascular Risk Factor Targets and Cardiovascular Disease Event Risk in Diabetes, a Pooling Project of the Atherosclerosis Risk in Communities Study, Multi-Ethnic Study of Atherosclerosis, and Jackson Heart Study","volume":"39","author":"Wong","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2017.06.015_bib31","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.atherosclerosis.2014.05.914","article-title":"Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets","volume":"235","author":"Toth","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2017.06.015_bib32","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1056\/NEJMoa1315878","article-title":"Daraplabib for preventing ischemic events in stable coronary heart disease","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2017.06.015_bib33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jacc.2015.10.058","article-title":"Utility of Nontraditional Risk Markers in Atherosclerotic Cardiovascular Disease Risk Assessment","volume":"67","author":"Yeboah","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2017.06.015_bib34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000331429","article-title":"Predictors of residual cardiovascular risk in patients on statin therapy for primary prevention","volume":"119","author":"Afonso","year":"2011","journal-title":"Cardiology"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287417303598?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287417303598?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T16:27:36Z","timestamp":1535646456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287417303598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S1933287417303598"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2017.06.015","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Residual atherosclerotic cardiovascular disease risk in statin-treated adults: The Multi-Ethnic Study of Atherosclerosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2017.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 National Lipid Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}